In-vitro Colorectal Cancer Screening Tests Market Trends Support A 6.8% CAGR Outlook Through The Forecast Period

The in-vitro colorectal cancer screening tests market is on track for significant expansion over the coming years, driven by advancements in technology and a growing emphasis on early cancer detection. This sector is evolving rapidly, fueled by innovations and increasing acceptance of personalized and convenient screening methods that aim to improve patient outcomes worldwide. Let's explore the market's forecasted growth, key players, emerging trends, and the primary segments shaping this industry's future.

Projected Market Size and Growth Trajectory of the In-vitro Colorectal Cancer Screening Tests Market
The global in-vitro colorectal cancer screening tests market is anticipated to reach a value of $1.82 billion by 2030. This represents a steady compound annual growth rate (CAGR) of 6.8% during the forecast period. The market's upward trajectory is largely attributed to the growing preference for personalized screening techniques, the rising popularity of at-home diagnostic kits, expansion of preventive healthcare programs, increased utilization of AI for interpreting results, and a stronger focus on affordable cancer screening options. Key market trends include the rising use of non-invasive tests, multi-target stool DNA assays, blood-based biomarker integration, home sample collection kits, and prioritization of early detection in individuals without symptoms.

The in-vitro colorectal cancer screening tests market size has grown strongly in recent years. It will grow from $1.3 billion in 2025 to $1.4 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to increasing colorectal cancer incidence rates, expansion of population screening programs, growing awareness of early cancer detection, availability of laboratory-based diagnostic infrastructure, improvements in biomarker identification.

Download a free sample of the in-vitro colorectal cancer screening tests market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27319&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Prominent Companies Leading the In-vitro Colorectal Cancer Screening Tests Industry
Several influential firms dominate this market, including:
Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers, Quest Diagnostics Incorporated, Roche Diagnostics International AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Natera Inc., BGI Genomics Co. Ltd., NeoGenomics Inc., Guardant Health Inc., CellMax Life Inc., Epigenomics AG, Acuamark Diagnostics Inc., Beacon Biomedical Inc., Mainz Biomed NV, Hologic Inc., Danaher Corporation, and Agilent Technologies Inc.

Notably, in February 2025, Mainz Biomed N.V., a biotech company based in Germany, formed a partnership with Switzerland's Labor Team W AG to roll out ColoAlert more widely across Switzerland. By leveraging Labor Team W AG's diagnostic network, the collaboration aims to enhance early detection of colorectal cancer and improve patient care. Labor Team W AG specializes in providing in-vitro colorectal cancer screening diagnostic services throughout the country.

View the full in-vitro colorectal cancer screening tests market report:
https://www.thebusinessresearchcompany.com/report/in-vitro-colorectal-cancer-screening-tests-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Innovations and Developments in the In-vitro Colorectal Cancer Screening Tests Market
Industry players are increasingly focused on refining diagnostic technologies to boost early detection rates and patient convenience, thereby reducing colorectal cancer mortality. Multi-target stool DNA tests are at the forefront of these innovations, as they analyze stool for genetic and biochemical markers linked to colorectal cancer and pre-cancerous abnormalities.

For example, in March 2025, Exact Sciences Corp., a molecular diagnostics firm based in the US, introduced Cologuard Plus. This enhanced at-home screening test targets average-risk adults aged 45 and older. It features cutting-edge biomarker technology that improves sensitivity and specificity compared to earlier versions. The test uses an advanced algorithm to detect DNA mutations and hemoglobin biomarkers, increasing the accuracy of identifying colorectal cancer and advanced adenomas. Cologuard Plus offers a non-invasive screening option that removes the need for bowel preparation or dietary restrictions, encouraging greater adherence to recommended screening schedules.

Detailed Segmentation of the In-vitro Colorectal Cancer Screening Tests Market
This market is categorized into several critical segments for better analysis:

1) By Test Type:
- Fecal Occult Blood Test
- Stool Deoxyribonucleic Acid Test
- Blood Biomarker Test
- Other Test Types

2) By Imaging Type:
- In-vitro Confirmatory Diagnostics
- Laboratory-Based Molecular Testing
- Companion Diagnostic Testing
- Genetic and Epigenetic Testing
- Biomarker Validation Testing
- Risk Stratification Assays

3) By Application:
- Screening
- Diagnosis
- Monitoring
- Risk Assessment
- Post-Treatment Surveillance

4) By End User:
- Hospitals
- Diagnostic Laboratories
- Outpatient Clinics
- Home Care Settings
- Research Institutions

Further subcategories include:
- Fecal Occult Blood Test: Guaiac Based Fecal Occult Blood Test, Immunochemical Fecal Occult Blood Test
- Stool Deoxyribonucleic Acid Test: Single Target Stool DNA Test, Multi Target Stool DNA Test
- Blood Biomarker Test: Methylated Septin 9 DNA Test, Circulating Tumor DNA Test, Protein Biomarker-Based Blood Test
- Other Test Types: Urine-Based Biomarker Test, Serum-Based Biomarker Test, Breath-Based Volatile Organic Compound Test

This comprehensive segmentation provides a detailed understanding of the in-vitro colorectal cancer screening tests market and highlights the diverse diagnostic approaches being developed and adopted to combat colorectal cancer effectively.

Our 2026 market reports now include enhanced strategic insights through:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.